<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437916</url>
  </required_header>
  <id_info>
    <org_study_id>20140131</org_study_id>
    <nct_id>NCT02437916</nct_id>
  </id_info>
  <brief_title>Safety Study of AMG 228 to Treat Solid Tumors</brief_title>
  <official_title>A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity,
      and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Subject incidence of dose limiting toxicities (DLT)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of treatment-emergent adverse events</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of treatment-related adverse events</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of clinically significant changes in vital signs and physical assessments</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of clinically significant changes in ECGs</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject incidence of clinically significant changes in clinical laboratory tests</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AMG 228 maximum observed concentration (Cmax)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AMG 228 minimum observed concentration (Cmin)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AMG 228 area under the concentration-time curve (AUC)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AMG 228 half-life (t1/2)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-AMG 228 antibody formation</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation status and changes in numbers of T regulator cells (Treg)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject objective response per immune-related Response Criteria (irRC)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation status of cytotoxic T lymphocytes (CTL)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in numbers of cytotoxic T lymphocytes (CTL)</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Tumors</condition>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Transitional Cell Carinoma of Bladder</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>AMG 228 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 228</intervention_name>
    <description>AMG 228 will be administered intravenously</description>
    <arm_group_label>AMG 228 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a pathologically documented, definitively diagnosed, advanced solid
             tumor

          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments

        Exclusion Criteria:

          -  Active autoimmune disease, history of autoimmune disease

          -  Treatment with immune modulators including

          -  Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors

          -  Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or
             investigational agent) within 28 days

          -  Major surgery within 28 days of study day 1
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>April 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Non-small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Head and Neck</keyword>
  <keyword>Transitional Cell Carinoma (TCC)</keyword>
  <keyword>Bladder</keyword>
  <keyword>Colorectal</keyword>
  <keyword>Colorectal Cancer (CRC)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
